Naratuximab is a humanized monoclonal antibody specifically targeting CD37 (TSPAN26), a tetraspanin protein widely expressed on the surface of B cells. This antibody exhibits high specificity and affinity for CD37, making it an ideal candidate for targeted therapeutic applications, including the development of antibody-drug conjugates (ADCs). Naratuximab serves as the foundation for the ADC compound Naratuximab emtansine, which combines the targeted binding properties of naratuximab with the cytotoxic agent emtansine, offering potential applications in the treatment of B-cell malignancies.
Naratuximab is a humanized monoclonal antibody specifically targeting CD37 (TSPAN26), a tetraspanin protein widely expressed on the surface of B cells. This antibody exhibits high specificity and affinity for CD37, making it an ideal candidate for targeted therapeutic applications, including the development of antibody-drug conjugates (ADCs). Naratuximab serves as the foundation for the ADC compound Naratuximab emtansine, which combines the targeted binding properties of naratuximab with the cytotoxic agent emtansine, offering potential applications in the treatment of B-cell malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
